June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Qayed, M.

S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3(S1):746-747, June 2019.

Author:
Qayum, N.
Author:
Qazilbash, M.

PS1389 IMPACT OF DIFFERENT MAINTENANCE THERAPY OPTIONS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AT MD ANDERSON CANCER CENTER

El Shazly, M.; Belal, A.A.; Farouk, M.; More

HemaSphere. 3(S1):636-637, June 2019.

PS1530 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY

Mehta, R.; Bassett, R.; Olson, A.; More

HemaSphere. 3(S1):706, June 2019.

PS1561 RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS

Khouri, I.; Milton, D.; Young, K.; More

HemaSphere. 3(S1):720, June 2019.

Author:
Qi, B.-Q.

PF233 CONSISTENCY OF GENOMIC ALTERATIONS ASSESSED BY NEXT-GENERATION SEQUENCING AMONG CIRCULATING TUMOR DNA, BONE MARROW AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN PEDIATRIC AML

Ruan, M.; Liu, C.; Qi, B.-Q.; More

HemaSphere. 3(S1):69, June 2019.

Author:
Qi, M.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3(S1):251, June 2019.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3(S1):616, June 2019.

Author:
Qian, J.
Author:
Qin, X.

S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN-IN RESULTS OF ANDROMEDA

Comenzo, R.L.; Kastritis, E.; Maurer, M.; More

HemaSphere. 3(S1):392, June 2019.

Author:
Qin, Y.-Z.

PB2361 INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3(S1):1052, June 2019.

Author:
Qiu, A.
Author:
Qiu, H.
Author:
Qiu, L.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

Tam, C.S.; Opat, S.; Zhu, J.; More

HemaSphere. 3(S1):526, June 2019.

Author:
Qiu, L.-G.
Author:
Quach, H.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

Weisel, K.; Spencer, A.; Lentzsch, S.; More

HemaSphere. 3(S1):251, June 2019.

PF604 THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB

Spencer, A.; Quach, H.; Horvath, N.; More

HemaSphere. 3(S1):255-256, June 2019.

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY

Gregory, G.; Walker, P.; Mahadevan, D.; More

HemaSphere. 3(S1):487, June 2019.

Author:
Quadvlieg, D.
Author:
Quah, C.
Author:
Quan, M.
Author:
Quaresmini, G.

PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY

Greil, R.; Fraser, G.; Leber, B.; More

HemaSphere. 3(S1):527, June 2019.

Author:
Quarta, A.
Author:
Quarta, C.

PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3(S1):958, June 2019.

Author:
Quattrone, M.
Author:
Queirós, A.

S843 THE PROLIFERATIVE HISTORY SHAPES THE DNA METHYLOME OF B-CELL TUMORS AND PREDICTS CLINICAL OUTCOME

Duran-Ferrer, M.; Clot, G.; Nadeu, F.; More

HemaSphere. 3(S1):376, June 2019.

Author:
Queizán, J.A.

S896 SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A.E.; More

HemaSphere. 3(S1):403-404, June 2019.

PF357 A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING

Pérez-Carretero, C.; Hernández-Sánchez, M.; González-Martínez, T.; More

HemaSphere. 3(S1):130-131, June 2019.

Author:
Quek, L.

PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3(S1):97, June 2019.

Author:
Quenet, S.

PF412 A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): SAFETY UPDATE AFTER 36 CYCLES OF TREATMENT

Hijiya, N.; Maschan, A.; Colombini, A.; More

HemaSphere. 3(S1):158, June 2019.

Author:
Querol, L.
Author:
Quesada, M.

PB2230 SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB-OZOGAMICIN

López-Pereira, P.; Figuera, Á.; Ormazábal, I.; More

HemaSphere. 3(S1):999-1000, June 2019.

Author:
Quesnel, B.

PS1041 TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH IDH2-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA – A FRENCH MEDICAL CHART REVIEW ANALYSIS

Pigneux, A.; Quesnel, B.; Thomas, X.; More

HemaSphere. 3(S1):470-471, June 2019.

Author:
Quezada, S.A.

PF563 MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

Alrasheed, N.; Lee, L.; Ghorani, E.; More

HemaSphere. 3(S1):233-234, June 2019.

Author:
Quick, D.

PF631 HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

Reece, D.; Bahlis, N.J.; Samaras, C.; More

HemaSphere. 3(S1):268-269, June 2019.

Author:
Quiery, A.T.

S830 AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

Radia, D.; Deininger, M.W.; Gotlib, J.; More

HemaSphere. 3(S1):368, June 2019.

PF357 A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING

Pérez-Carretero, C.; Hernández-Sánchez, M.; González-Martínez, T.; More

HemaSphere. 3(S1):130-131, June 2019.

S896 SYNTHETIC LETHAL EFFECTS OF DUAL BCR AND PARP INHIBITION IN PROLIFERATIVE DEL(11Q) CLL CELLS IN THE PRESENCE OF STROMAL STIMULATION

Quijada-Álamo, M.; Hernández-Sánchez, M.; Rodríguez-Vicente, A.E.; More

HemaSphere. 3(S1):403-404, June 2019.

Author:
Quilichini, B.

PB1868 B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3(S1):851-852, June 2019.

Author:
Quint, K.D.

PF509 MOLECULAR ANALYSIS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG TYPE AT DIAGNOSIS AND RELAPSE – IMPLICATIONS FOR TARGETED THERAPIES

Schrader, A.M. R.; de Groen, R.A. L.; Willemze, R.; More

HemaSphere. 3(S1):207-208, June 2019.

Author:
Quintana, G.

PB1901 IBRUTINIB, SINGLE AGENT BTK INHIBITOR, FOR RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD EXPERIENCE FROM RETE EMATOLOGICA PUGLIESE (REP).

Scalzulli, P.R.; Guarini, A.; Loseto, G.; More

HemaSphere. 3(S1):866-867, June 2019.

Author:
Quintarelli, C.

S1635 ACADEMIC, PHASE1 TRIAL ON T CELLS EXPRESSING BOTH CD19 CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA AND NON-HODGKIN LYMPHOMA

Del Bufalo, F.; Merli, P.; Vinti, L.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Quintero, G.

PB2124 OVERALL SURVIVAL OF MULTIPLE MYELOMA (MM) PATIENTS IN COLOMBIA: REPORT OF THE COLOMBIAN REGISTRY FOR HEMATO-ONCOLOGICAL DISEASES (RENEHOC) ASOCIACIÓN COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA (ACHO)

Melo, C. Sossa; Abello, V.; Idrobo, H.; More

HemaSphere. 3(S1):956-957, June 2019.

Author:
Quinto, A. M.

PB2130 REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA

Mele, G.; Pastore, D.; Di Renzo, N.; More

HemaSphere. 3(S1):959, June 2019.

Author:
Quiroga, L.

PS1402 OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM

Peña, C.; Schutz, N.P.; Bove, V.; More

HemaSphere. 3(S1):643-644, June 2019.

Author:
Quota, A.
Author:
Quraishy, M.
Show: